Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japanese Regulators, With Drug Makers Support, Moves Toward East Asian Clinical Data Sharing And Acceptance

This article was originally published in PharmAsia News

Executive Summary

Japan is determined to further an initiative in promoting multi-regional clinical study data acceptance among East Asian countries, and the proposal has gained critical support from the nation's drug making industry

You may also be interested in...



Bayer Global Regulatory Affairs Head Joseph Scheeren On MRCT In China: An Interview With PharmAsia News

The possibility China may scale back the acceptance of Multi-Regional Clinical Trial (MRCT) data has become a hot topic between China FDA and industry. On the sidelines of a recent special Asia Pacific Economic Cooperation (APEC) meeting on regional clinical trials, Joseph Scheeren, head of global regulatory affairs for Bayer, shares his views.

Islands Dispute Hits Japan Device Sales In China While Pharma Less Affected

Both Japanese and Chinese device makers have reported lower sales and profits linked to a rift over disputed islands, potentially signaling a lengthy period of strained trade ties.

U.S. Private Equity Stake In CMIC Shows Rosy Outlook For Japan's Contract Research Market

TOKYO - U.S. private equity firm Taiyo Pacific Partners secured a 5 percent stake in CMIC, Japan's largest CRO, highlighting the CRO market growth potential in Japan, despite increased focus on R&D outsourcing to China and India

Related Content

UsernamePublicRestriction

Register

LL1132440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel